Oligometastatic Disease, Pancreatic Ductal Adenocarcinoma
Conditions
Keywords
Hepatic metastasis, Pulmonary metastasis, Oligometastasis, Surgical Resection
Brief summary
Surgical Resection of Synchronous Pulmonary or Hepatic Oligometastatic Pancreatic Ductal Adenocarcinoma (PHOLIPANC). This is an interventional, open-label, non-randomised, single-arm phase II clinical trial. Eligible patients with hepatic or pulmonary oligometastatic adenocarcinoma of the pancreas must have received neoadjuvant FOLFIRINOX chemotherapy in cycles of 14 days, or other clinically indicated alternative. FOLFIRINOX is not a study treatment.
Detailed description
In this clinical trial the investigators will enroll subjects with hepatic or pulmonary oligometastatic pancreatic ductal adenocarcinoma and perform a synchronous surgical resection. In patients with progressive disease during or after the first four cycles of neoadjuvant chemotherapy, those patients will not be eligible for study enrollment. Patients with tumor response or stable disease after the first 4-cycles but a non-resectable primary tumor according to the evaluation of an interdisciplinary tumor board must receive 4 more cycles of neoadjuvant chemotherapy before being evaluated for eligibility for the Study Entry Screening. Patients with hepatic metastasis with tumor response or stable disease and a resectable primary tumor after the first 4 cycles can undergo explorative laparotomy and synchronous resection of the tumor and hepatic metastases, if feasible. In patients who undergo exploratory laparotomy and are deemed to have unresectable disease by the surgeon, the patients may receive 4 more cycles of neoadjuvant chemotherapy 2-4 week after surgery, before the patient will be re-evaluated for the eligibility for the Study Entry Screening. Patients with pulmonary metastasis with tumor response or stable disease and a resectable primary tumor after the first 4 cycles can undergo resection of the primary tumor followed by resection of pulmonary metastases or vice versa, if feasible. All eligible patients with hepatic metastasis will undergo exploratory laparotomy surgery and synchronous resection of the tumor and hepatic metastases, if feasible according to the surgeon, 2-6 weeks after the last neoadjuvant chemotherapy treatment. All eligible patients with pulmonary metastasis will undergo resection of the primary tumor followed by resection of pulmonary metastases or vice versa, if feasible.
Interventions
PROCEDURESurgery
All eligible patients with hepatic metastasis will undergo exploratory laparotomy surgery and synchronous resection of the tumor and hepatic metastases, if feasible according to the surgeon, 2-6 weeks after the last neoadjuvant chemotherapy treatment. All eligible patients with pulmonary metastasis will undergo resection of the primary tumor followed by resection of pulmonary metastases or vice versa, if feasible
Sponsors
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 100 Years
Healthy volunteers
No
Inclusion criteria
1. Inclusion Criteria at the Pre-Screening Enrollment * Histologically confirmed diagnosis of treatment-naïve limited hepatic or pulmonary metastatic adenocarcinoma of the pancreas Meet the definition of limited hepatic or pulmonary metastasis according to CT/MRI that is done prior to the starting of any anticancer treatment. Either CT scan of chest, abdomen, and pelvis with intravenous contrast or a combination of MRI of abdomen and pelvis and CT scan of chest is acceptable radiographic imaging. CT/MRI can be done at an outside facility, but must be reviewed by a Johns Hopkins Medicine radiologist. * Measurable disease according to RECIST v1.1 * Eastern Cooperative Oncology Group (ECOG) performance status 0-1 * Being a candidate for the chemotherapy with FOLFIRINOX or modified FOLFIRINOX * Patients ≥18 years at the time of signing the informed consent * Patient's written informed consent prior to any trial-specific procedure * Patient's legal capacity to consent to participation in the clinical trial 2.
Exclusion criteria
at the Pre-Screening Enrollment * Acinar cell carcinoma and/or neuroendocrine carcinoma of the pancreas * Symptomatic clinically significant ascites * Evidence of any distant metastases other than limited hepatic or pulmonary metastasis as defined in inclusion criterion 1. * Evidence of simultaneous pulmonary and hepatic metastases * Any tumor-specific pretreatment of the adenocarcinoma of the pancreas (including but not limited to surgery, radiation therapy, chemotherapy or ablative procedures). Currently being on FOLFIRINOX or modified FOLFIRINOX (mFOLFIRINOX) is allowed, unless more than 2 treatments of FOLFIRINOX or mFOLFIRINOX has been given. * Any malignancies other than adenocarcinoma of the pancreas in the 2 years before the start of the clinical trial except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, breast cancer, prostate cancer or superficial bladder tumors (Ta, Tis and T1) * Known HIV seropositivity * Known active or chronic Hepatitis B or Hepatitis C infection * Any other severe concomitant disease or disorder, which could influence patient's ability to participate in the clinical trial and his/her safety during the trial or interfere with interpretation of results, e.g., severe hepatic, renal, pulmonary, cardiovascular, metabolic or psychiatric disorders 3.2 Eligibility Criteria for Study Entry Enrollment at the Pre-Surgery phase 3.2.1 Inclusion Criteria for study continuation at the Pre-Surgery phase * ECOG performance status 0-1 * Received FOLFIRINOX, modified FOLFIRINOX or the further modified forms including FOLFIRI, FOLFOX, 5FU or capecitabine. Liposomal irinotecan is permitted. Switching to gemcitabine/nal-paclitaxel due to intolerability of FOLFIRINOX is also permitted. * Radiographical evidence of disease response or stable disease with CA19-9 decrease \> 20% from the baseline or CA19-9 that is not detectable * Patients ≥18 years at the time of signing the informed consent * Patient's written informed consent prior to any trial-specific procedure * Patient's legal capacity to consent to participation in the clinical trial 3.2.2
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| 2-year overall survival will be measured for the evaluable liver and Lung oligometastasis patient cohorts, respectively, and compare to historical controls. | 48 months | Time-to-event data will be analyzed according to the Kaplan-Meier method (product-limit analysis). Patients who are not known to have had an event by the time of the analyses will be censored based on the last recorded date the patient was known to be event-free. |
| Compare the Intrametastasis effector T cell infiltration | 48 months | The liver oligometastasis cohort and the lung oligometastasis cohort will be compared in terms of intra-tumoral CD8+ T cells. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Perioperative morbidity and mortality as assessed by the Common terminology criteria for adverse events | 48 months | The safety analysis includes type, incidence, and severity of adverse events (severity according to Common terminology criteria for adverse events version 5.0). |
| Medium Overall Survival (OS) and Disease Free Survival | 48 months | Kaplan-Meier survival curves will be constructed to summarize disease free survival and overall survival, respectively. |
| Health-related quality of life will be assessed by the European organization for research and treatment of cancer quality of life questionnaire (EORTC QLQ-C30) | 48 months | Questions 1 to 28, a 4-point scale is used, ranging from 1 ("Not at all") to 4 ("Very much"), with lower scores indicating a more positive outcome. Questions 29 and 30 employ a 7-point scale, with scores ranging from 1 ("Very poor") to 7 ("Excellent"), where higher scores signify a better outcome |
| Health-related quality of life as assessed by the European Organisation for Research and Treatment of Cancer in Pancreatic Cancer (EORTC QLQ-PAN26) | 48 months | European Organisation for Research and Treatment of Cancer in pancreatic cancer includes 26 questions with two subscales: functioning scales (4 questions),and symptom scales (22 questions). The functional scale, the higher the total score, the better the quality of life; the lower the score in the symptom scale, the better the quality of life. All scores are scaled to range from 0-100. |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORJin He, MD, PhD
Johns Hopkins University
Outcome results
None listed